This inventor holds 1 USPTO granted patent. Top assignees: Novozymes A/s, Solvay Pharmaceuticals, Gmbh. Active years: 2011.
Company Filing History:
1 out of 1,417 
1 out of 77 
Years Active: 2011
Title: Peter Collin Gregory: Innovator in Pharmaceutical Amylases
Introduction
Peter Collin Gregory is a notable inventor based in Hanover, DE. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on amylases. His research focuses on the pharmaceutical applications of these enzymes, which play a crucial role in various medical treatments.
Latest Patents
Peter Collin Gregory holds 1 patent for his invention titled "Amylases for pharmaceutical use." This patent details the use of alpha-amylases related to SEQ ID NOs: 1-3, which can be combined with lipases and/or proteases. The medical indications for this invention include the treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, and both type I and type II diabetes. The amylases described in his patent exhibit improved efficacy in vivo, enhanced pH profiles, high specific activity, and superior starch degradation profiles.
Career Highlights
Throughout his career, Peter has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Novozymes A/S and Solvay Pharmaceuticals GmbH. His expertise in enzyme technology has been instrumental in advancing pharmaceutical applications.
Collaborations
Peter has collaborated with various professionals in his field, including his coworker Allan Svendsen. Their joint efforts have contributed to the development of innovative solutions in enzyme applications.
Conclusion
Peter Collin Gregory's work in the field of pharmaceutical amylases showcases his dedication to improving medical treatments through innovative enzyme technology. His contributions continue to impact the pharmaceutical industry positively.